Market Newsdesk

TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, will speak at the Jefferies Virtual West Coast Consumer Conference on Tuesday, November 17, 2020 at 1:10 p.m. EST.

The webcast will be available on the Investors section of the Company’s website at ir.thecronosgroup.com/events-presentations.

About Cronos Group Inc.

Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos Group is building an iconic brand portfolio. Cronos Group’s portfolio includes PEACE NATURALS™, a global health and wellness platform, two adult-use brands, COVE™ and Spinach™, and three hemp-derived CBD brands, Lord Jones™, Happy Dance™ and PEACE+™. For more information about Cronos Group and its brands, please visit: www.thecronosgroup.com.

Forward-looking Statements
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include the Company’s intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (as amended), the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2020, the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2020, the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2020 and the Company’s definitive proxy statement dated April 28, 2020, all of which have been filed on SEDAR and EDGAR and can be accessed at www.sedar.com and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos Group disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

Cronos Group Contact

Anna Shlimak
Tel: (416) 504-0004
[email protected]

In connection with the release of Golden Ocean’s third quarter 2020 results in the morning (CET) of Thursday, November 19, 2020, a teleconference/webcast will be held as described below:

Teleconference and webcast

A conference call will be held at 03:00 P.M. CET (09:00 A.M. New York Time) on Thursday, November 19, 2020. The presentation will be available for download from the Investor Relations section at www.goldenocean.bm (under “Presentations”) prior to the teleconference/webcast.

In order to listen to the presentation you may do one of the following:

a. Webcast
Click the “Webcast” link on www.goldenocean.bm

b. Conference Call
PARTICIPANTS DIAL IN TELEPHONE NUMBERS

Participants will be asked for their full name & Conference ID. The Conference ID is 8433555.

Please download the presentation material from www.goldenocean.bm in order to follow the presentation slides while listening to the conference.

REPLAY DETAILS (available for 7 days)

Participant list information required: Full Name & Company

November 13, 2020

Hamilton, Bermuda

This information is subject to the disclosure requirements of section 5-12 of the Norwegian Securities Trading Act.

Cary, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) — CPESN USA, a clinically integrated, nationwide organization of pharmacy networks created to advance community-based pharmacy practice, was announced today as a Federal Pharmacy Partner (Network Administrator) for the CDC COVID-19 Vaccination Program. Click here to see the full announcement from the U.S. Department of Health and Human Services.

“We are humbled to be able to participate in the federal COVID-19 vaccine program, said Troy Trygstad, PharmD, MBA, PhD, executive director with CPESN® USA. “We strongly believe that local pharmacies are trusted and accessible – two critical elements for a successful nationwide campaign to immunize against this pandemic.”

Inclusion in the federal government’s COVID-19 vaccination program would not have been possible without tireless support of the National Community Pharmacists Association (NCPA).

“NCPA continues to the trumpet the important role independent, community-based pharmacies can play in the vaccine effort,” offered Jay Williams, director of marketing and communications for CPESN® USA. “Their role in getting us involved – along with other Federal Pharmacy Partners who represent independent pharmacies – cannot be understated.”

CPESN® Networks continue to expand across the country with 50 local networks in 45 states plus the District of Columbia. These pharmacy providers have emerged and joined the movement to provide patients, physicians, and payers with enhanced medication-use and patient-care services that have been proven to improve patient health and lower costs.

“The COVID-19 pandemic has been life altering for Americans,” said Cody Clifton, PharmD, director of practice transformation and clinical programs for CPESN® USA. “Now, CPESN pharmacies are able to exemplify their trusting relationships with patients in their local communities to take a major step in getting our country back to normal. We believe this is a great opportunity to demonstrate the value of community-based pharmacies!”

About CPESN® USA
CPESN® USA a clinically integrated, nationwide organization of pharmacy networks structured to advance community-based pharmacy practice. They empower community-based pharmacies that are deeply rooted within their community by fostering their ability to provide high quality, patient-centered enhanced services. CPESN® pharmacies integrate with other healthcare providers on the patient’s care team to coordinate medical treatment. The results are better medication adherence, higher patient satisfaction, and lower healthcare costs. You can find CPESN® Networks of pharmacy providers in 45 states across America. To learn more, please visit www.CPESN.com.

# # #

MIRAMICHI, New Brunswick, Nov. 13, 2020 (GLOBE NEWSWIRE) — SLAM Exploration Ltd. (“SLAM” or the “Company” on TSXV: SXL) is pleased to announce results for 282 soil samples collected from the vicinity of Zone 9 where new discoveries of quartz veins No 18 and No 22 with multiple sites of visible gold were recently reported in the Company’s news releases issued October 20, 2020 and October 26, 2020. Zone 9 is located about 600m south of the Maisie gold vein within the Company’s wholly-owned Menneval gold project in northwestern New Brunswick.

The Company collected 281 soils samples at 25m intervals on 8 grid lines spaced 100 metres apart and on an additional line at 50 m spacing in the vicinity of recently discovered gold veins. Elevated levels of gold ranging from 5 to 683 parts per billion (“ppb”) occur in 92 of the samples. These include 79 samples containing gold in the range 5 to 20 ppb and 12 samples with gold in the range 21 to 57 ppb. One sample contains 683 ppb gold at an untested site about 25 m north of Zone 9.

Elevated gold levels in the soil indicate potential for extensions of the Maisie vein system to the west, south and east of the known gold veins in the vicinity of Zone 9. The soil anomalies are open in all 3 directions showing potential to extend further. The gold values are shown in thematic form on the attached map.

The Company received the positive soil results after it had dug trench M20-22 which uncovered vein No 22, a 550m long vein with one section mineralized with limonite, goethite and pyrite over a strike length of 180m and at least one site of visible gold reported. Since then, the Company has continued digging cross trenches and has uncovered a series of en echelon veins extending 800m northeast of vein No 22. This expands the Menneval vein system to an area with a north-south dimension of 1,200 m from the northern tip of the Maisie gold vein to the southern tip of vein No. 22 and an east-west dimension of 1,200 m. The vein system is open to the east of the new vein discoveries.

The Company continues the trenching program to discover veins using an excavator and to collect grab samples of vein material. The current focus is to discover as many veins as possible by a series of cross trenches and by grab sampling to identify the higher grade areas. The Company is currently trenching to test for potential new veins and extensions associated with gold soil anomalies south and west of Zone 9.

Assays are pending on 56 grab samples collected from trenches M20-18 to 22, some containing visible gold as reported October 26, 2020. In addition, 45 samples collected from trenches M20-23 to 33 are being shipped to the lab. Results are still pending from 282 soil samples that may assist the Company in the search.

Following this trenching program, the Company expects a potential resumption of diamond drilling activities to test these new gold occurrences. The exploration program is supported in part by a $30,000 contribution to the Menneval gold project under the New Brunswick Junior Mining Assistance Program. Mike Taylor, President & CEO of SLAM, presented a powerpoint to illustrate these new discoveries on Tuesday, October 27, 2020 at the EMP Zoom Conference hosted by the New Brunswick Department Of Natural Resources And Energy (“NBDNRE”). For information please visit:
https://www2.gnb.ca/content/gnb/en/departments/erd/energy/content/conference/Conf_home.html

The Menneval Project: The Menneval Gold project is now comprised of 480 claim units covering 10,460 hectares located in northwestern New Brunswick. The Company holds a 100% interest in the Menneval claims with the exception of 4 claim units covering 105 hectares that are subject to a 1.5% NSR. The Company can buy down 0.5% of the NSR for $500,000 and it has the right of first refusal on the remaining 1% NSR.

About SLAM Exploration Ltd:

SLAM is a project-generating resource company with a portfolio of precious metal and base metal properties in New Brunswick and Ontario. The Company owns the Menneval Gold project and the Lewis Brook silver project in northern New Brunswick, as well as 5 gold projects located in the vicinity of Clarence Stream where Galway Gold Inc. has reported successful gold drilling results in southern New Brunswick. SLAM also owns the Reserve Creek, Opikeigen and Miminiska gold projects in Ontario. The Company owns a portfolio of base metal properties in the Bathurst Mining Camp (“BMC”) that is subject to an option agreement. SLAM also holds NSR royalties on the Superjack, Nash Creek and Coulee zinc‐lead‐copper‐silver properties in the BMC. Additional information about SLAM and its projects is available at www.slamexploration.com or from SEDAR filings at www.sedar.com. Follow us on twitter @SLAMGold.

QA-QC –
Sampling Procedures

Soil samples were collected by GeoXplore Surveys Inc of Bathurst NB and delivered directly to ALS Geochemistry in Moncton New Brunswick for gold analysis using Au-A23, a fire assay with AAS finish. I

Qualifying Statements:
Mike Taylor P.Geo, President and CEO of SLAM Exploration Ltd., a qualified person as defined by National Instrument 43-101, approves the technical information contained in this news release.

Certain information in this press release may constitute forward-looking information, including statements
that address the Private Placement, the closing of the Private Placement, future production, reserve
potential, exploration and development activities and events or developments that the Company expects.
This information is based on current expectations that are subject to significant risks and uncertainties
that are difficult to predict. Actual results might differ materiall
y from results suggested in any
forward-looking
statements. The Company assumes no obligation to update the forward-looking statements, or to
update the reasons why actual results could differ from those reflected in the forward looking-statements
unless and until required by securities laws applicable to the Company. There are a number of risk
factors that could cause future results to differ materially from those described herein. Information
identifying risks and uncertainties is contained in the Company’s filings with the Canadian securities
regulators, which filings are available at www.sedar.com. Neither the TSXV nor its Regulation Services
Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or
accuracy of this release.

CONTACT INFORMATION:

Mike Taylor, President & CEO
Contact: 506-623-8960 [email protected]

Eugene Beukman, CFO
Contact: 604-687-2038 [email protected]                                 SEDAR: 00012459E

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dd24f3fb-0cb8-42fb-ba6b-5a1803cecf84

Wakefield, MA, Nov. 13, 2020 (GLOBE NEWSWIRE) — The i2b2 tranSMART Foundation, a global non-profit open-source foundation advancing the development of clinical and translational research through effective collaboration, has been awarded a grant to support the initial deployment of three key initiatives to advance COVID-19 research.

COVIDAuthors.org is a new website containing searchable online profiles of more than 200,000 researchers who have written scientific articles related to COVID-19. It shows which authors have written articles together and illustrates how scientists from many different disciplines have come together to study this worldwide pandemic. Policy makers can use the website to find experts around the world by research topic or geographic region. Funding agencies can track the impact of their investments into COVID-19 research. Investigators can search for collaborators for new COVID-19 research studies. COVIDAuthors.org is powered by Profiles Research Network Software, which was developed by Harvard Catalyst, Harvard’s Clinical and Translational Science Center (Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541).

The Foundation, in cooperation with the Axiomedix and the Open Source Pharma Foundation, is holding a Datathon on November 18-20, 2020.  This Datathon will focus on collaborative data science to better understand the coronavirus and related SARS and MERS viruses, potentially leading to new scientific knowledge and ultimately improvement in patient care. Publicly available datasets relating to the viruses are available in the tranSMART v19 platform on the Foundation Library server to facilitate collaboration. A suite of data exploration and analysis tools will also be available. Participating data scientists will collaborate to identify potential cross-disease biomarkers to advance our understanding of disease pathophysiology and to inform new therapeutic approaches. Leading scientific software vendors and developers will be available to assist throughout the Datathon. The Datathon will be held virtually using the Zoom conferencing system.  See https://i2b2transmart.org/virtual-datathon-2020.                                                                                    

For more information about these projects and their availability, please see the i2b2 tranSMART website at www.i2b2transmart.org. The  projects received support from a grant from Dell Technologies.

About The i2b2 tranSMART Foundation – The i2b2 tranSMART Foundation is a global non-profit open-source organization focused on realizing the promise of precision medicine.  It provides open-source software and databases representing more than 250 million patient lives to thousands of physicians and scientists worldwide.  Its data and analytics platforms help academic, non-profit, healthcare, government and commercial research communities effectively conduct collaborative research.  The Foundation is headquartered in Wakefield, Massachusetts.  The i2b2 tranSMART Foundation can also be found on the web at www.i2b2tranSMART.org.   

###

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Interface, Inc. (“Interface” or the “Company”) (NASDAQ: TILE) in the United States District Court for the Eastern District of New York on behalf of those who purchased or acquired the securities of Interface between March 2, 2018 and September 28, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Interface investors under the federal securities laws.

The Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (ii) consequently, Interface reported artificially inflated income and earnings per share (“EPS”) in 2015 and 2016; (iii) Interface and certain of its employees were under investigation by the Securities and Exchange Commission (“SEC”) with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC’s investigation, and downplayed the true scope of the Company’s wrongdoing and liability with respect to the SEC investigation; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On April 24, 2019, Defendants filed a current report on Form 8-K with the SEC, disclosing that Interface “received a letter in November 2017 from the [SEC] requesting that the Company voluntarily provide information and documents in connection with an investigation into the Company’s historical quarterly [EPS] calculations and rounding practices during the period 2014-2017”; that “[t]he Company subsequently received subpoenas from the SEC in February 2018, July 2018 and April 2019 requesting additional documents and information”; and that “[i]n the fourth quarter of 2018, the Company conducted at the SEC’s request an internal investigation into these and other related issues for seven quarters in 2015, 2016 and 2017.” On this news, Interface’s stock price fell $1.43 per share, or 8.37%, to close at $15.66 per share on April 25, 2019.

Then, on September 28, 2020, the SEC announced the conclusion of its investigation into Interface’s historical quarterly EPS calculations and rounding practices. Interface agreed to pay a $5 million fine to resolve the matter and was ordered to cease and desist from violating the federal securities laws. In the SEC’s enforcement order issued that same day, the SEC also disclosed how, inter alia, “Interface employees caused Interface to produce documents in response to Commission investigative requests that were suggestive of contemporaneous support for journal entries that, in truth, did not exist at the time the entries were recorded,” and had modified certain documents after the SEC’s investigation began. On this news, Interface’s stock price fell $0.20 per share, or 3.13%, over the following two trading sessions to close at $6.18 per share on September 29, 2020

Investors who purchased or otherwise acquired shares of Interface during the Class Period should contact the Firm prior to the January 11, 2021 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].

Please visit our website at http://www.gme-law.com for more information about the firm.

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the common stock of Golar LNG Limited (“Golar” or the “Company”) (NASDAQ: GLNG) between April 30, 2020, and August 10, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the Central District of California alleges violations of the Securities Exchange Act of 1934.

If you purchased Golarsecurities, and/or would like to discuss your legal rights and options please visit GLNG Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations and prospects. Specifically, Defendants misrepresented and/or failed to disclose to investors: (1) that certain employees, including Hygo’s CEO, had bribed third parties, thereby violating anti-bribery policies; (2) that, as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) that, as a result of the foregoing reputational harm, Hygo’s valuation ahead of its IPO would be significantly impaired; and (4) that, as a result of the foregoing, Defendants positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On September 24, 2020, media reported that Hygo’s CEO Eduardo Navarro Antonello was involved in a bribery network investigated in Brazil’s Operation Car Wash.

On this news, the Company’s share price fell $3.28.

If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Golarsecurities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/golarlnglimited-glng-shareholder-class-action-lawsuit-stock-fraud-315/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information
Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]